Clinical Research Services to Bolster Digital PCR and Real-time PCR Market Growth During 2024-2031

According to our new research study on "Digital PCR and Real-time PCR Market Forecast to 2031 - Global Analysis - by Product and Services, Applications, End User, and Type" the market is expected to grow from US$ 17.54 Bn by 2031 from US$ 9.55 Bn in 2024; it is estimated to grow at a CAGR of 9.1% during 2024-2031. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the market growth.

Polymerase chain reaction (PCR) is a nearly ubiquitous, robust, and reliable technology used in most molecular biology labs to amplify specific stretches of DNA for genotyping, cloning, and analysis of single nucleotide variations. It even serves as the basis for most next-generation sequencing (NGS) preparation. Technological advancements are yielding different types of PCR techniques. The use of PCR technology has now been explored into several non-conventional applications, making molecular diagnosis easier and faster. In particular, advancements in digital and real-time PCR are used to diagnose diseases, identify viruses and bacteria, and aid forensic investigations.

Moreover, the researchers are trying to reduce test time using some nanomaterials. In March 2023, the Center for Augmented Safety System with Intelligence, Sensing of the Korea Institute of Science and Technology (KIST, President: Seok Jin Yoon) announced the development of an ultrafast PCR technology by Dr. Sang Kyung Kim (Director) and Dr. Seungwon Jung's research team. The ultrafast PCR reduces the test duration by ten times compared to the previous test by utilizing photothermal nanomaterials. The diagnostic performance of the new method is similar to the current test method, and it can be completed in just 5 minutes.

In September 2021, Thermo Fisher Scientific, the world leader in serving science, launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

Thus, technological advancements in PCR technologies propel the digital PCR and real-time PCR market growth.

The Digital PCR and Real-time PCR Market is segmented on the basis of product and services, application, end user, type and geography. The Digital PCR and Real-time PCR Market, based on product and services, is segmented into instruments, reagents and consumables and software and services. The reagents and consumables segment held the largest share of the Digital PCR and Real-time PCR Market in 2024. In terms of applications, the Digital PCR and Real-time PCR Market is segmented into infectious diseases testing, oncology testing, blood screening, transplant diagnostics and others. The infectious diseases testing segment held a larger share of the Digital PCR and Real-time PCR Market in 2024. Based on end user, the market is segmented into Hospitals and diagnostic centers, research laboratories and academic institutes, pharmaceutical and biotechnology companies, clinical research organizations and forensic laboratories. The hospitals and diagnostic centers segment held the largest share of the Digital PCR and Real-time PCR Market in 2024. By type, the Digital PCR and Real-time PCR Market is divided into Digital PCR and Real-time PCR. The Real-time PCR segment held the largest share of the Digital PCR and Real-time PCR Market in 2024

In terms of geography, the Digital PCR and Real-time PCR Market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). The US holds the largest market share, followed by Canada. The North America digital PCR and real-time PCR market is expanding rapidly, driven by a growing need for advanced molecular diagnostics, particularly in cancer detection, infectious disease testing, and genetic research. With a well-established healthcare system, significant government funding, and continuous advancements in biotechnology, the region has become a global leader in PCR adoption. One of the most significant factors fueling this growth is the rising cancer burden. According to the American Cancer Society (2025), an estimated 1.9 million new cancer cases were diagnosed in the US in 2022, with 609,360 deaths attributed to the disease. PCR technology plays a vital role in early cancer detection, identifying genetic mutations, and monitoring treatment response, all of which are critical for improving survival rates. The demand for high-sensitivity tests, such as liquid biopsies using dPCR, has surged, helping detect rare mutations in blood samples without invasive procedures. Beyond oncology, PCR is extensively used in infectious disease diagnostics, particularly after the COVID-19 pandemic highlighted the importance of rapid, accurate testing. Hospitals and diagnostic labs are investing in point-of-care (PoC) PCR devices, which allow for quicker disease detection in emergency settings and remote locations. Pharmaceutical and biotech companies are also integrating PCR into drug development and personalized medicine, leveraging its precision to identify biomarkers and tailor treatments for patients. While qPCR remains the dominant technology, dPCR is gaining ground due to its unmatched accuracy in detecting low-abundance DNA and RNA sequences. This makes it particularly useful in areas such as rare disease research, forensic testing, and environmental monitoring. However, challenges such as high equipment costs, complex regulatory approvals, and the need for specialized training have slowed widespread adoption. A dPCR system can exceed US$ 100,000, making it unaffordable for smaller labs and research centers. Despite these hurdles, North America continues to lead the global digital PCR and real-time PCR market, driven by cutting-edge research, increasing automation, and the growing adoption of AI-powered data analysis. As the healthcare industry moves toward more personalized and precision-driven treatments, PCR will remain at the forefront, offering faster and more reliable diagnostic solutions that improve patient outcomes.

QIAGEN NV, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Takara Bio Inc, Agilent Technologies Inc, bioMerieux SA, Danaher Corp, Abbott Laboratories, and Countable Labs are among the key players in the market.

Companies operating in the Digital PCR and Real-time PCR Market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the Digital PCR and Real-time PCR Market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the developments made by the companies operating in Digital PCR and Real-time PCR Market are as follows:

- In February 2025, - bioM